TRAVERSE trial showed no increase in MACE with testosterone therapy, improving sexual function and depression symptoms without affecting diabetes or prostate cancer outcomes. T4DM trial found a 13% ...
In determining the best treatment, urologist Arpeet Shah, MD, stresses the importance of thorough diagnostics. In this video, recorded at the 2025 LUGPA Annual Meeting, Arpeet Shah, MD, a urologist ...
DSUI's 2025 report emphasizes advancements in urology through visionary leadership, innovation, and transformative technologies, including AI-powered diagnostics and interdisciplinary research. Dr.
This segment centers on the landmark EMBARK trial, which demonstrated a significant overall survival benefit with enzalutamide plus leuprolide. Freedland discusses the clinical implications of these ...
212Pb-ADVC001 is a PSMA-targeted alpha-emitting radioligand therapy. According to Hansen, 212Pb-ADVC001 is a PSMA-targeted alpha-emitting radioligand therapy (RLT) being developed for patients with ...
Data suggest that KIM-1 is prognostic for clinical outcomes in aRCC. A retrospective analysis of the COSMIC-313 trial (NCT03937219) suggests that KIM-1 is prognostic for clinical outcomes and may ...
Aaron R. Hansen, BSc, MBBS, FRACP, highlights key findings from the theraPb trial, exploring the safety and preliminary efficacy of ADVC001 in mCRPC.
Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025. Host Amy Pearlman, MD, discusses premature ejaculation with Brian L. Steixner, MD, a ...
A panel of experts discusses the evolution of BPH treatment, as well as how their practices have been affected by COVID-19.
Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate cancer. The trial showed consistent benefits across clinical endpoints, ...
The ARASAFE study showed significant reductions in grade 3-5 adverse events and grade 3-4 neutropenia or death with a 50 mg/m2 docetaxel regimen. Despite a higher cumulative docetaxel dose, the 50 ...
The NIAGARA trial showed that adding durvalumab to neoadjuvant chemotherapy in MIBC patients did not negatively impact HRQOL outcomes. Significant improvement in event-free survival was observed with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback